SCHEDULE: Medicus Pharma: Hathaway's 4.5% Stake Disclosed
Beneficial Ownership Report
John Hathaway and SkinJect Partners LLC report a 4.5% passive ownership stake in Medicus Pharma Ltd. through a Schedule 13G amendment.
Summary
- John Hathaway and SkinJect Partners LLC, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Medicus Pharma Ltd.
- The Reporting Persons beneficially own an aggregate of 800,952 common shares of Medicus Pharma Ltd.
- This ownership represents 4.5% of the company's common shares outstanding.
- The percentage is calculated based on 17,816,266 common shares reported by Medicus Pharma Ltd. as outstanding as of August 11, 2025, in its Quarterly Report on Form 10-Q.
- SkinJect Partners LLC directly holds the 800,952 shares, and John Hathaway is deemed the beneficial owner due to his control over SkinJect Partners LLC, though he disclaims beneficial ownership except to the extent of his direct ownership (which is zero).
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a passive ownership stake and does not contain information that would significantly alter the fundamental outlook or performance expectations for the company. It is neutral in sentiment.
Positives
- A notable investor, John Hathaway, maintains a significant passive stake in Medicus Pharma Ltd., which could be viewed as a vote of confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a passive ownership stake and does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that Medicus Pharma Ltd. is a publicly traded entity with a disclosed shareholder base.
Stakeholder Impact
- Shareholders are informed of a significant passive ownership stake held by John Hathaway and SkinJect Partners LLC, providing transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which required the filing of this statement. |
| 08/11/2025 | Date as of which Medicus Pharma Ltd. reported 17,816,266 common shares outstanding in its Quarterly Report on Form 10-Q. |
| 08/12/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
| 02/10/2025 | Date of previously filed Schedule 13G, which included the Joint Filing Agreement. |
Recommendation
holdThis Schedule 13G filing is a disclosure of a passive ownership stake below the 5% threshold, indicating no intent to influence control or operations. It provides no new information regarding Medicus Pharma Ltd.'s financial performance, strategic direction, or operational outlook. Therefore, it does not present a basis for a change in investment recommendation; a 'hold' stance is appropriate as existing investment theses remain unchanged by this disclosure.
Keywords
Medicus Pharma, John Hathaway, SkinJect Partners, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.